Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Forecasts Global Molnupiravir Revenues Of $5bn-$7bn Through 2022

Executive Summary

Assuming emergency use authorization of the antiviral to fight COVID-19 in December, Merck expects to make $500m-$1bn this year. It will share profits equally with partner Ridgeback.

You may also be interested in...



Merck Sees Options For Molnupiravir Past Pandemic

The antiviral for COVID-19 added $952m to Merck's top line in 2021 and is forecast to deliver $5bn-$6bn in 2022, but CEO Davis sees potential for the product beyond the current pandemic, including potential combinations.

Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments

Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.

Wave Of Molnupiravir Generics In India Amid Early Physician Cheer

India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of  Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel